HomeAbout

TL;DR CNBC


Wegovy rival to be part of a suite of weight loss drugs, Roche CEO says following positive trial results - TL;DR CNBC

Wegovy rival to be part of a suite of weight loss drugs, Roche CEO says following positive trial results

Publishing timestamp: 2024-07-25 08:45:28


Summary

Roche's weight loss drugs show promising early stage trial results, aiming to combat obesity and associated health risks. The company believes they have a competitive edge in the growing obesity medication market and is open to further acquisitions to strengthen their portfolio. Analysts are looking forward to more trial data in September.


Sentiment: POSITIVE

Tickers: NOVO.B-DK

Keywords: novo nordisk a/sbusiness newsbiotechnologybiotech and pharmaceuticalspharmaceuticals

Source: https://www.cnbc.com/2024/07/25/roche-wegovy-obesity-rival-to-be-part-of-a-suite-of-weight-loss-drugs.html


Developed by Leo Phan